Results 21 to 30 of about 5,863 (219)

Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine [PDF]

New England Journal of Medicine, 2009
The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first pandemic of the 21st century. Development of effective vaccines is a public health priority.We conducted a single-center study, involving 176 adults, 18 to 50 years of age, to test the monovalent influenza A/California/2009 (H1N1) surface-antigen vaccine, in both MF59-adjuvanted ...
Clark, Tristan, Pareek, Manish, Höschler, Katja, Dillon, Helen, Nicholson, Karl G, Groth, Nicola, Stephenson, Iain   +6 more
openaire   +4 more sources

Altered response to A(H1N1)pnd09 vaccination in pregnant women: a single blinded randomized controlled trial. [PDF]

PLoS ONE, 2013
Pregnant women were suspected to be at particular risk when H1N1pnd09 influenza became pandemic in 2009. Our primary objective was to compare the immune responses conferred by MF59®-adjuvanted vaccine (Focetria®) in H1N1pnd09-naïve pregnant and non ...
Anne Louise Bischoff, Nilofar Vahman Følsgaard, Charlotte Giwercman Carson, Jakob Stokholm, Louise Pedersen, Maria Holmberg, Amalie Bisgaard, Sune Birch, Theodore F Tsai, Hans Bisgaard   +9 more
doaj   +1 more source

A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration [PDF]

, 2014
Strategies to optimize responses to seasonal influenza vaccination in older adults include the use of adjuvants, higher antigen doses, and intradermal delivery.
Castellino, Flora, Clement, Frédéric, Del Giudice, Giuseppe, Della Cioppa, Giovanni, Galli, Grazia, Groth, Nicola, Leroux-Roels, Geert, Levin, Yotam, Lindert, Kelly, Nicolay, Uwe   +9 more
core   +1 more source

MF59^®‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis [PDF]

Influenza and Other Respiratory Viruses, 2008
Abstract  Influenza is a major cause of worldwide morbidity and mortality through frequent seasonal epidemics and infrequent pandemics. Morbidity and mortality rates from seasonal influenza are highest in the most frail, such as the elderly, those with underlying chronic conditions and very young children. Antigenic mismatch between strains recommended
Banzhoff, Angelika, Pellegrini, Michele, Del Giudice, Giuseppe, Fragapane, Elena, Groth, Nicola, Podda, Audino   +5 more
openaire   +2 more sources

Development of MF-59 adjuvant using chitosan derivatives to influenza vaccine [PDF]

Journal of Advanced Biomedical Sciences, 2020
Background & Objective: The influenza virus causes hundreds of deaths in the world. Despite the availability of some authorized vaccines for all age groups and its approved beneficial effects, the influenza is still a major problem for public health ...
Alireza Loghmani, Nowruz Delirezh, Afagh Moattari   +2 more
doaj  

Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization. [PDF]

PLoS ONE, 2014
In an open label clinical study (2007), MF59-adjuvanted hemagglutinin (HA) vaccine from H5N1-A/Vietnam/1194/2004 (clade 1) was administered to subjects previously vaccinated (primed) with clade 0 H5N3 (A/duck/Singapore/97) vaccine at least 6 years ...
Surender Khurana, Elizabeth M Coyle, Milena Dimitrova, Flora Castellino, Karl Nicholson, Giuseppe Del Giudice, Hana Golding   +6 more
doaj   +1 more source

Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age [PDF]

, 2014
Background: Vaccines against pandemic A/H1N1 influenza should provide protective immunity in children, because they are at greater risk of disease than adults.
Abarca, Katia, Arora, Ashwani, Della Cioppa, Giovanni, Kieninger-Baum, Dorothee, Knuf, Markus, Lattanzi, Maria, Leroux-Roels, Geert, Pedotti, Paola, Rivera, Luis, Rümke, Hans C   +9 more
core   +2 more sources

Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium [PDF]

, 2019
Funding text The authors are grateful for the vital contributions of the participating study volunteers, clinicians, nurses, and laboratory technicians at the Surrey study site.
Bodinham, C., Bottazzi, B., DelGiudice, G., Denoel, P., Greenwood, A., Jonsdottir, I., Kaufmann, S., Kester, K., Leroux-Roels, G., Lewis, D., Linley, C., Maertzdorf, J., Mantovani, A., Mollenkopf, H., Pizzoferro, K., van den Berg, R., Weiner, J.   +16 more
core   +1 more source

Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis [PDF]

European Journal of Immunology, 2001
The mechanisms associated with the immunostimulatory activity of vaccine adjuvants are still poorly understood. We have undertaken a study to determine whether antigen-presenting cell trafficking is modified by administration of the submicron emulsion adjuvant MF59.
M, Dupuis, K, Denis-Mize, A, LaBarbara, W, Peters, I F, Charo, D M, McDonald, G, Ott   +6 more
openaire   +2 more sources

Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants.

PLoS ONE, 2012
Adjuvant formulations capable of inducing high titer and high affinity antibody responses would provide a major advance in the development of vaccines to viral infections such as HIV-1. Although oil-in-water emulsions, such as Freund's adjuvant (FCA/FIA),
Rachel P J Lai, Michael S Seaman, Paul Tonks, Frank Wegmann, David J Seilly, Simon D W Frost, Celia C LaBranche, David C Montefiori, Antu K Dey, Indresh K Srivastava, Quentin Sattentau, Susan W Barnett, Jonathan L Heeney   +12 more
doaj   +1 more source